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Purpose:  Anti-rheumatic agents target common molecular pathways of inflammation in rheumatoid arthritis (RA) and peri-
odontitis. The purpose of this study was to determine the relative effect of anti-rheumatic agents on the levels of inflammato-
ry biomarkers and periodontal inflammation in RA patients with periodontitis. 
Methods:  A systematic review and meta-analysis were conducted of studies comparing periodontal parameters of inflamma-
tion, such as bleeding on probing, and biomarkers of inflammation in RA patients with periodontitis and healthy adults with 
and without periodontitis. The search included the electronic databases MEDLINE, Cochrane Database of Systematic Reviews, 
and Google Scholar, inclusive through October 2011, with no language restrictions. Hand searches were conducted of the bib-
liographies of related journals and systematic reviews. Observational and interventional studies assessing the effects of anti-
rheumatic therapy qualified for inclusion. Two reviewers performed independent data extraction and risk-of-bias assessment. 
Of the 187 identified publications, 13 studies fulfilled the inclusion criteria. 
Results: When compared to healthy adults without periodontitis, RA subjects were found to have significantly higher levels 
of bleeding on probing and limited evidence of higher levels of interleukin-1β and tumor necrosis factor-α (TNF-α) in gingi-
val crevicular fluid and saliva. No consistent differences were found in periodontal parameters and inflammatory biomarkers 
between RA subjects and adults with periodontitis. Studies evaluating the effect of anti-TNF-α therapy in RA subjects with 
periodontitis have yielded inconsistent results. 
Conclusions: There are limited data, however, to suggest that anti-TNF-α agents can reduce local production of inflammato-
ry cytokines and periodontal inflammation in RA patients with periodontitis.
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INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoimmune disease 
affecting 0.5 to 1.0% of the population, with women carrying 
a disproportionately higher risk (3:1) of disease than men [1]. 
RA is a polyarthritis characterized by chronic inflammation, 
synovial hyperplasia, and intra-articular fibrin deposition 
leading to destruction and deformity of the joint architecture 
and function. Similar to chronic periodontitis, the clinical 
onset of RA frequently occurs after the ages of 35 years. Al-
though the etiology of RA remains incompletely understood, 
the initiation and propagation of the disorder have been at-
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tributed to multiple factors, including low-grade infection 
and auto-antigens. Sustained elevations in pro-inflammatory 
mediators following disease initiation, such as subclinical in-
fection, appear necessary for progression [2].
Overlapping molecular pathways of inflammation have 
been implicated in periodontitis and rheumatoid arthritis.
Periodontitis has been associated with elevations in circulat-
ing levels of tumor necrosis factor-α (TNF-α), interleukin-6 
(IL-6), and C-reactive protein (CRP) [2]. Moreover, Porphy-
romonas gingivalis has been associated with an enhanced in-
flammatory response expressed by higher CRP levels [3]. Peri-
odontitis and RA are characterized by similar humoral and 
cellular immune responses and a common immunogenetic 
profile [4]. Microscopically, the inflammatory lesions and tis-
sue destruction observed in RA share similarities with those 
found in periodontitis [5]. Local tissue destruction involves 
the production of inflammatory cytokines and proteolytic 
proteins, such as matrix metalloproteinases (MMPs) [6]. The 
prevalence of RA in patients with periodontitis has been 
found to be nearly four times the rate of the general popula-
tion (3.95% vs. 1%, respectively) [7]. The association of peri-
odontitis with RA appears to be independent of other risk 
factors, including cigarette smoking, socioeconomic status, 
body mass index, alcohol consumption, and poor oral hy-
giene [8]. 
Several hypotheses have been advanced to explain the as-
sociation between RA and periodontitis. Evidence of Porphy-
romonas gingivalis, Tannerella forsythensis and Prevotella inter-
media has been identified in the synovial fluid in RA, suggest-
ing that periodontal pathogens play a role in disease initia-
tion or propagation [9]. Viral infections have been implicated 
as an environmental risk factor for rheumatoid arthritis [10] 
and periodontitis [11]. Antibodies against cyclic citrullinated 
peptide have been identified in many RA patients [12]. Citrul-
lination is the post-translational conversion of arginine resi-
dues to citrulline residues by the enzyme peptidylarginine 
deiminase (PAD) [13]. P. gingivalis has been shown to express 
the PAD protein and may play a crucial role in the pathogen-
esis of periodontitis-associated RA [5]. Collectively, these ob-
servations suggest that common molecular pathways under-
lie each of these inflammatory conditions [2].
The presence of shared underlying inflammatory pathways 
mediating the progression of periodontitis and RA should 
provide potentially important common therapeutic targets. 
The purpose of this study, therefore, was to determine the 
relative effect of anti-rheumatic agents (Table 1) on levels of 
periodontal inflammation and inflammatory biomarkers in 
RA patients with periodontitis. A systematic review and me-
ta-analysis were conducted of studies comparing periodontal 
parameters of inflammation and biomarkers of inflammation 
in RA patients with periodontitis and healthy adults with and 
without periodontitis.
MATERIALS AND METHODS
Study selection and interventions
The eligibility criteria for inclusion in thesystemic review 
were: 1) human subjects with RA undergoing anti-rheumatic 
therapy, 2) evaluation of periodontal indices or biomarkers of 
inflammation in serum, saliva, or gingival crevicular fluid, 3) 
case-control or randomized controlled study design, and 4) 
English language publications. Exclusion criteria included 
case reports and review articles (Fig. 1).
Data sources and search
The bibliographical databases MEDLINE, Cochrane Data-
base of Systematic Reviews, and Google Scholar were searched 
up to and including October 2011 for studies examining the 
effects of anti-rheumatic therapy on periodontal status and 
biomarkers of inflammation in serum, saliva, or gingival cre-
Table 1.  Drugs used in the treatment of rheumatoid arthritis.
Type of drugs Therapeutic agent Target Disadvantages
NSAIDs Aspirin Inhibition of the 
synthesis of 
cyclooxygenase
No change in the 
progression of disease
Naproxen
Diclofenac
Ibuprofen
DMARDs Methotrexate Change the 
progression of 
disease
Toxicity
Leflunomide No change in the 
progression of erosive 
articular damage
Sulphasalazine
Hydoxychloroquine
Anti-
cytokines
Infliximab Tumor necrosis 
factor-α
Infection, malignancy
Etanercept
Adalimumab
Golimumab
Certolizumab
Anakinra Interleukin (IL)-1 Limited efficacy in 
reducing progression of 
disease, infection risk
Tocilizumab IL-6 Potential to affect host 
defense
Abatacept T-cell activation Infection risk
Rituximab B-cell depletion Infection risk
NSAIDs: non-steroidal anti-inflammatory drugs, DMARDs: disease modifying 
antirheumatic drugs.Journal of Periodontal
& Implant Science JPIS
Ji Young Han and Mark A. Reynolds 5
vicular fluid (GCF) in RA subjects. In addition to the online 
search, a hand search was conducted of the bibliographies of 
the articles identified and their related journals.
The authors assessed all data independently and disagree-
ments were resolved by discussion. Online search terminol-
ogy included “periodontitis and/or rheumatoid arthritis” and 
“drug(s) and/or anti-TNF-α or therapy.” Abstracts were also 
identified that required full text access to assess inclusion or 
exclusion in this systematic review. For the second-stage 
screening, studies using the same population surveys or da-
tabases were identified to avoid duplicate inclusion. Full text 
copies were obtained of the remaining non-excluded articles. 
In the final screening, full-text papers were eligible for inclu-
sion provided that data were available on the periodontal 
status and biomarkers of inflammation.
Data extraction and quality assessment
In addition to the basic features of research design, data 
were extracted on the biomarkers of inflammation (e.g., CRP, 
IL-1β, TNF-α) and clinical measures of periodontal status, in-
cluding gingival inflammation and bleeding on probing. 
Measures of bacterial plaque accumulation were also record-
ed for comparison. 
Studies evaluating the effect of anti-rheumatic agents in 
RA subjects permitted comparisons with 1) healthy subjects, 2) 
periodontitis subjects, and 3) RA subjects not on anti-rheu-
matic agents. The Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses statement [14] was used as a 
general guideline for communicating the results of this in-
vestigation.
Statistical analysis
The mean final score for each outcome measure was sub-
mitted to a meta-analysis, including an assessment for het-
erogeneity (Comprehensive Meta-Analysis, Biostat Inc., En-
glewood, NJ, USA). Meta-analysis permitted comparisons of-
subjects between groups (RA vs. healthy) as well as a compar-
ison of RA subjects based on treatment with anti-TNF-α 
medication. A meta-analysis comparing the standard differ-
ence in means (SDM) was computed for each outcome mea-
sure, when data were available from 3 or more studies, using 
a random-effects model, with an α-level set at P≤0.05. Stud-
ies in the analysis were weighted according to the number of 
subjects contributing scores in each treatment group.
RESULTS
The initial online search identified 187 publications, with 
Figure 1.  Flowchart of literature identification, screening, eligibility, and inclusion process. RA: rheumatoid arthritis, PO: periodontitis, 
TNF-α: tumor necrosis factor-α.
Records identified through 
database search (n=187)
Records after duplicates removed 
(n=189)
Records obtained from first screen 
(n=104)
Full text articles assessed for eligibility 
(n=33)
Analysis comparing  
RA vs. PO (n=13)
Analysis comparing anti TNF-α(+)  
vs. anti TNF-α(-) in 
RA group (n=4)
Analysis comparing  
RA vs. Healthy control  
group (n=13)
Final studies included (n=13)
First screen excluded (n=85)
Second screen excluded (n=71)
Final screen excluded (n=20)
Additional records identified 
through other sources (n=2)Journal of Periodontal
& Implant Science JPIS
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only 13 studies fulfilling the inclusion criteria (Table 2). Four 
studies comparing RA subjects to healthy adults without 
periodontitis were excluded from analysis because the stud-
ies did not include selection criteria defining periodontal 
status [15-18]; however, one of these studies [16] also provided 
comparative data for RA subjects and healthy subjects with 
periodontitis and therefore, the study was included in this 
analysis. The RA subjects were treated with one or more anti-
rheumatic therapies, including corticosteroids, non-steroidal 
anti-inflammatory drugs, disease modifying antirheumatic 
drugs (DMARDs), biologics, or anti-TNF-α agents [15-27]. 
Studies included RA subjects with periodontitis [15,18-24,26]. 
The RA subjects without periodontitis in one study were ex-
cluded from the analysis [27]. Methodological quality or risk 
of bias in the studies was considered moderate.
Comparison of RA subjects with periodontitis and healthy 
subjects without periodontitis
RA subjects were found to have significantly higher plaque 
index (PI) scores than healthy subjects without periodontitis 
(SDM=1.6; Z=3.1; P≤0.05); however, heterogeneity in PI 
scores between studies was significant (Q-value=49.8; 
P≤0.001) [15-17,19-22,24,26,27]. Higher mean gingival index 
(GI) scores in RA subjects than healthy subjects were reported 
in 2 studies [21,22]. Five studies provided comparative data 
demonstrating higher levels of bleeding on probing (BOP) 
[19-21,24,25] in RA subjects with periodontitis than healthy 
subjects without periodontitis (SDM=1.6; Z=4.2; P≤0.001) 
(Table 3). The heterogeneity in GI scores between studies was 
significant (Q-value=19.8; P≤0.001).
Some limited comparative data are available on the levels 
of inflammatory markers (IL-1β, IL-6, and IL-10) in RA sub-
jects receiving anti-rheumatic therapy and healthy subjects 
without periodontitis [15,18,19,21,23,25] (Table 3). IL-1β levels 
were found to be higher in RA subjects in 2 of 3 studies 
[17,19,25]; however, the overall mean difference in IL-1β levels 
between subjects did not differ significantly (SDM=0.48; 
Z=1.76; P≤0.08). The variability in differences in IL-1β levels 
between studies was not significant (Q-value=4.7; P≥0.05). 
Higher levels of TNF-α were found in the saliva [25] but not 
the serum [23] of RA subjects compared to healthy subjects. 
RA subjects were also reported to have higher circulating 
CRP [24] and crevicular fluid MMP-8 [20] levels than healthy 
subjects.
Table 3.  Comparison of inflammatory biomarkers and periodontal parameters in RA subjects and healthy subjects without periodontitis.
Study Study design
Healthy 
(No.)
RA 
(No.)
Anti-rheumatic 
therapy
Periodontal 
status of RA 
subjects
Source
Biomarker
Periodontal 
measure
IL-1β TNF-α IL-6 IL-10 MMP-8 CRP PI GI BOP
Bozkurt et al.  
[21] (2000)
Case-control 15 15 Corticosteroid
NSAIDs
DMARDs
Periodontitis GCF NS ↑ ↑ ↑a)
Havemose-
Poulsen et al.  
[23] (2005)
Cross-sectional 25 22 Corticosteroid
NSAIDs
DMARDs
Periodontitis Serum NS NS NS ↑
Biyikoglu et al. 
[19] (2006)
Case-control 17 10 Corticosteroid
NSAIDs
Periodontitis GCF ↑ ↑ ↑
Bozkurt et al.  
[22] (2006)
Case-control 17 17 Corticosteroid
NSAIDs
DMARDs
Periodontitis GCF ↓ ↑ ↑
Havemose-
Poulsen et al.  
[24] (2006)
Case-control 25 22 Corticosteroid
NSAIDs
DMARDs
OP
N-OP
Periodontitis   Serum ↑ NS NS
Biyikoglu et al. 
[20] (2009)
Case-control 24 13 Corticosteroid
NSAIDs
Periodontitis GCF ↑ ↑ ↑
Mirrielees et al. 
[25] (2010)
Case-control 35 35 DMARDs
Anti-TNF 
medication
Periodontitis
b) Saliva ↑ ↑ NS ↑
RA: rheumatoid arthritis, IL-1β: interleukin-1β, TNF-α: tumor necrosis factor-α, MMP-8: matrix metalloproteinase-8, CRP: C-reactive protein, PI: plaque index, GI: gingival 
index, BOP: bleeding on probing, NSAIDs: non-steroidal anti-inflammatory drugs, DMARDs: disease modifying anti-rheumatic drugs, GCF: gingival crevicular fluid, OP: 
opioid analgesics, N-OP: non-opioid analgesics, NS: P >0.05,↑: significantly higher in RA subjects (P<0.05), ↓: significantly lower in RA subjects (P<0.05).
a)Sulcus bleeding index, 
b)Included subjects without periodontitis.Journal of Periodontal
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Comparison of RA subjects with periodontitis and healthy 
subjects with periodontitis
Table 4 presents a comparison of RA subjects with peri-
odontitis to otherwise healthy subjects with periodontitis. 
Similar levels of plaque deposits (SDM=0.7; Z=0.5; P≥0.05) 
and gingival inflammation, as reflected in BOP scores 
(SDM=0.52; Z=0.80; P≥0.05), were found in RA and healthy 
subjects with periodontitis. Significant heterogeneity in PI 
scores (Q-value=41.4; P≥0.05) and BOP scores (Q-value=
76.4; P≥0.05) was found between studies.
With the exception of IL-β, evaluations of each biomarker-
have been limited to a single study [19-22,25]. Significantly 
lower levels of IL-β [25], lower levels of TNF-α [25], and high-
er levels of IL-4 [22] have been reported in RA and healthy 
subjects with periodontitis. 
Effects of anti-TNF-α agents in RA subjects with periodon-
titis
Limited evidence is available on the effectiveness of anti-
TNF-α agents in reducing periodontal inflammation and in-
flammatory biomarkers in RA subjects with periodontitis 
(Tables 5 and 6). Two studies reported lower mean GI scores 
in RA subjects receiving anti-rheumatic agents plus anti-
TNF-α drugs compared to RA subjects receiving only anti-
rheumatic agents. Three studies reported BOP scores in RA 
subjects receiving anti-TNF-α drugs; however, there was no 
overall effect of anti-TNF-α agents on BOP scores (SDM=
-1.64; Z=-1.56; P≥0.05), reflecting, in part, the significant het-
erogeneity among studies (Q-value=25.7; P≤0.001) [16,25,26]. 
Two case-control studies have reported lower TNF-α levels 
in GCF and serum of RA subjects receiving anti-TNF-α drugs 
compared to non-treated RA subjects [16,25]. Mirrielees et al. 
[25] also found significantly lower serum IL-1β levels in RA 
Table 4.  Comparison of inflammatory biomarkers and periodontal parameters in RA and healthy subjects with periodontitis.
Study Study design
Anti-rheumatic
therapy
Peri-
odontitis 
(No.)
RA  
(No.)
Periodontal 
status of RA 
subjects
Source 
Biomarker Periodontal measure
IL-1β TNF-α IL-6 IL-4 IL-10 MMP-8 PI GI BOP
Bozkurt et al.  
[21] (2000)
Case-control Corticosteroid
NSAIDs
Chloroquine
15 15 Periodontitis GCF NS ↑ NS NS
a)
Biyikoglu et al. 
[19] (2006)
Case-control Corticosteroid 
NSAIDs
17 10 Periodontitis GCF NS NS NS
Bozkurt et al.  
[22] (2006)
Case-control Corticosteroid
NSAIDs
Chloroquine
17 17 Periodontitis GCF ↓ NS NS NS
Biyikoglu et al. 
[20] (2009)
Case-control Corticosteroid
NSAIDs
25 13 Periodontitis GCF NS NS NS
Mirrielees et al. 
[25] (2010)
Case-control DMARDs
Anti-TNF 
medication
35 35 Periodontitis
b) Saliva ↓ ↓ ↓ ↓
RA: rheumatoid arthritis, IL-1β: interleukin-1β, TNF-α: tumor necrosis factor-α, MMP-8: matrix metalloproteinase-8, PI: plaque index, GI: gingival index, BOP: bleeding on 
probing, NSAIDs: non-steroidal anti-inflammatory drugs, GCF: gingival crevicular fluid, DMARDs: disease modifying anti-rheumatic drugs, NS: P>0.05, ↑: significantly 
higher in RA subjects (P<0.05), ↓: significantly lower in RA subjects (P<0.05).
a)Sulcus bleeding index, 
b)Included subjects without periodontitis.
Table 5.  Studies evaluating the effectiveness of anti-TNF-α agents in RA subjects.
Study Duration of RA 
(years±SD)
Periodontal status
Anti-TNF-α therapy positive (RA [+]) Anti-TNF-α therapy negative (RA [-])
Age (year) Smokers Age (year) Smokers
Pers et al. [27] (2008) Not specified Periodontitis
a) 53.2±8.2 5/20 (25%) 55.4±12 11/20 (55%)
Mayer et al. [16] (2009) RA(+):16.4±12.12
RA(-):4.6±2.12
Periodontitis
a) 53.6±9.23 3/10 (30%) 47.1±16.1 3/10 (30%)
Ortiz et al. [26] (2009) Not specified Periodontitis 39-87 (median, 63) Not specified 42-68 (median, 49) Not specified
Mirrielees et al. [25]  
(2010)
At least 3 years after 
diagnosis
Periodontitis
a) 46.8±10.5 RA(+) + RA(-): 11.4% 46.8±10.5 RA(+) + RA(-): 11.4%
TNF-α: tumor necrosis factor-α, RA: rheumatoid arthritis, NS: P>0.05.
a)Included some subjects without periodontitis.Journal of Periodontal
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subjects receiving anti-TNF-α drugs compared to non-treat-
ed RA subjects.
DISCUSSION
Multiple observational studies [2,28] and experimental 
studies in laboratory animals have established an association 
between RA and periodontitis [29,30]. RA and periodontitis 
share many similarities in pathophysiology and clinical pro-
gression [2]. Early studies suggested that non-steroidal in-
flammatory agents might hold promise in controlling the 
progression of these disorders; however, this class of drugs 
has shown minimal or no effect on RA [31] and periodontitis 
[32]. The development of new anti-rheumatic agents, includ-
ing DMARDs and biologics, that target specific molecular 
factors in the inflammatory cascade, offers the potential to 
slow or arrest the progression of these disorders [33].
In this systematic review, we examined the relative effect of 
anti-rheumatic agents on the levels of inflammatory biomark-
ers and periodontal inflammation in RA patients with peri-
odontitis. Of particular interest were studies comparing the 
periodontal and inflammatory profile of RA patients on dif-
ferent anti-rheumatic agents to otherwise healthy adults with 
and without periodontitis. Studies were case-controlled in 
design [16,19-27], using study populations of convenience, 
with only one study matching for age and gender [25]. The 
smoking status of subjects was generally adjusted for in the 
statistical analysis, although 3 studies did not specify the 
smoking status of subjects [21-23]. RA was diagnosed accord-
ing to the criteria of the American College of Rheumatology 
[34] in all but 3 studies, which did not specify the criteria for 
diagnosis [21,22,26]. The duration of RA was highly variable, 
ranging from 1 year to over 25 years; however, the duration 
from the time of diagnosis or treatment was not provided in 
2 studies [22,23].
Currently, non-steroidal anti-inflammatory drugs and ste-
roids are used early in treatment to reduce inflammation and 
pain and to slow joint damage in RA patients. Disease modi-
fying antirheumatic drugs, including methotrexate, lefluno-
mide, hydroxychloroquine, sulphasalazine, and minocycline, 
and immunosuppressants are frequently necessary to slow 
the progression of erosive articular damage over time. The 
latter drugs, however, are associated with significant risk of 
liver damage, bone marrow suppression, and severe lung in-
fections [35]. Biologic therapies targeting cytokines also have 
been successfully used in controlling RA [35]. The latter agents 
block or antagonize the actions of TNF-alpha, which is con-
sidered the “master regulator” of the inflammatory response 
in both RA [36] and periodontitis [37].
Most studies compared RA patients with periodontitis to 
healthy adults without evidence of destructive periodontal 
disease [19-25]. RA patients were found to have higher plaque 
scores and BOP scores compared to healthy patients without 
periodontitis. Of the available studies examining the biomark-
ers of inflammation, the majority compared GCF or salivary 
levels rather than serum levels [16,21-23,25]. Limited compar-
ative data are available on the inflammatory biomarkers in 
RA patients compared to systemically healthy patients with-
out periodontitis. Levels of IL-1β and TNF-α were found to 
be higher in the GCF and saliva [17,19,25], but not the serum 
[23], in RA patients with periodontitis compared to healthy 
subjects without periodontitis. Higher levels of TNF-α were 
found in the saliva [25] but not the serum [23] of RA subjects. 
These latter studies provide limited evidence suggesting that 
elevations in local but not systemic levels of these inflamma-
tory cytokines are present in RA patients, despite anti-rheu-
matic treatment, compared to healthy persons without peri-
odontitis. Consistent with elevations in local TNF-α expres-
sion, RA patients were also found to have higher BOP scores 
compared to healthy controls.
RA patients on anti-rheumatic agents were found to exhibit 
lower local IL-1β and TNF-α levels than otherwise healthy 
patients with periodontitis. Local IL-4 levels were also found 
to be lower in RA patients than in periodontitis patients. Lim-
Table 6.  Association of anti-TNF-α medication with levels of inflammatory biomarkers and periodontal inflammation in RA subjects.
Author Study design Total
Periodontal status  
of RA subjects
No. of anti-
TNF-α(+)
No. of anti-
TNF-α(-) Source
Biomarker Periodontal measure
IL-1β TNF-α PI GI BOP
Pers et al. [27] (2008)
a) Case-control 17 Periodontitis 8 9 NS ↑b) ↑c)
Mayer et al. [16] (2009) Case-control 20 Periodontitis
a) 10 10 GCF ↓ NS ↓ ↓
Ortiz et al. [26] (2009) Case-control
d) 20 Periodontitis 10
e) 10 NS NS NS
Mirrielees et al. [25] 
(2010)
Case-control 35 Periodontitis
a) 18 17 Saliva ↓ ↓ ↓
RA: rheumatoid arthritis, IL-1β: interleukin-1β, TNF-α: tumor necrosis factor-α, PI: plaque index, GI: gingival index, BOP: bleeding on probing, NS: P>0.05, ↑: significantly 
higher in RA subjects (P<0.05), ↓: significantly lower in RA subjects (P<0.05).
a)Included subjects without periodontitis, 
b)Modified gingival index, 
c)Papillary bleeding index, 
d)Administration of anti-TNF-α was not randomized, 
e)Pre- and post-treatment 
comparison.Journal of Periodontal
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ited data suggest that RA patients receiving anti-TNF-α med-
ication may exhibit lower local IL-1β and TNF-α levels as well 
as less gingival inflammation, based on GI and BOP scores, 
than patients with periodontitis. However, interpretation of 
this evidence is necessarily limited due, in part, to both the 
observational design and small number of studies.
Smoking is a significant modifiable risk factor for periodon-
titis [38]. Recent research suggests that long-term smoking 
markedly increases the risk of RA in men and women [39]. 
One possible mechanism for the higher prevalence of peri-
odontitis in RA patients may reflect the increased risk for oral 
colonization by P. gingivalis, a causative agent of periodonti-
tis [40]. These observations are consistent with the hypothe-
sis that P. gingivalis, which expresses PAD, plays a crucial role 
in the initiation and/or propagation of periodontitis-associ-
ated RA [5]. In studies included in this meta-analysis, the per-
centage of RA subjects that smoked ranged from about 7 to 
41%; however, 2 studies excluded smokers and 2 studies did 
not specify the smoking status.
Ortiz et al. [26] reported that anti-TNF-α therapy without 
periodontal treatment had no significant effect on the peri-
odontal condition. RA patients receiving periodontal treat-
ment had a significant decrease in the mean RA disease ac-
tivity score, the erythrocyte sedimentation rate, and serum 
TNF-α level. However, there was no clinical improvement in 
these parameters in patients that did not receive periodontal 
treatment. Anti-TNF-α therapy resulted in a significant im-
provement in gingival inflammation, BOP scores, and the 
clinical attachment level [26]. Pers et al. [27] evaluated the im-
pact of an anti-TNF-α agent administered over a period of 
nearly 2 years on the periodontal status of 40 subjects with 
RA. Clinical attachment loss was significantly reduced after 
anti-TNF-α treatment, suggesting that TNF-α blockade in 
RA patients can limit periodontal breakdown. These results 
are consistent with the hypothesis that anti-TNF-α treatment 
is effective in improving periodontal status and reducing the 
biomarkers of inflammation.
RA and periodontitis share many similarities in pathophys-
iology and clinical progression, suggesting that treatment of 
RA with anti-rheumatic agents, particularly anti-TNF-α agents, 
may reduce the progression of destructive periodontal dis-
ease. Currently, insufficient evidence is available to deter-
mine whether traditional anti-rheumatic agents are benefi-
cial in controlling periodontitis. There are limited data, how-
ever, suggesting that anti-TNF-α agents can reduce local 
production of inflammatory cytokines and periodontal in-
flammation in RA patients with periodontitis. Future studies 
are warranted to examine the benefits of TNF-α therapy in 
controlling periodontal inflammation and breakdown. 
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